Company
Jazz Pharmaceuticals
Jazz Pharmaceuticals has 38 drugs tracked on RxWires: 3 post-market, 9 in Phase 3, 3 in Phase 2/3, 15 in Phase 2, 1 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Solriamfetol | Post-Market | Binge Eating Disorder |
| JZP-258 | Post-Market | Narcolepsy |
| Cannabidiol Oral Solution | Post-Market | Lennox-Gastaut Syndrome |
| Nabiximols | Phase 3 | Spasticity With Multiple Sclerosis |
| Dociparstat | Phase 3 | Acute Myeloid Leukemia |
| GW-1000-02 | Phase 3 | Pain |
| Zanidatamab | Phase 3 | Biliary Tract Cancer |
| Xyrem® | Phase 3 | Fibromyalgia |
| Brincidofovir | Phase 3 | Adenovirus Infection |
| GWP42003-P 20 mg/kg/day Dose | Phase 3 | Epilepsy |
| Sativex | Phase 3 | Pain |
| Defibrotide | Phase 3 | Severe Hepatic Veno-Occlusive Disease |
| Tetrahydrocannabinol | Phase 2/3 | Pain, Postoperative |
| JZP926 capsule | Phase 2/3 | Juvenile Myoclonic Epilepsy |
| Sodium Oxybate | Phase 2/3 | Binge Eating Disorder |
| CPX-351 | Phase 2 | Acute Myeloid Leukemia (AML) |
| Cytarabine | Phase 2 | Leukemia |
| Lurbinectedin | Phase 2 | Extensive-stage Small-cell Lung Cancer |
| ZW25 (Zanidatamab) | Phase 2 | HER2-amplified Biliary Tract Cancers |
| Dordaviprone (ONC201) | Phase 2 | Glioma |
| CBD Oral Solution | Phase 2 | Fragile X Syndrome |
| Fludarabine | Phase 2 | Hematologic Malignancy |
| GWP42003-P | Phase 2 | Autism Spectrum Disorder |
| ONC201 | Phase 2 | Meningioma |
| ONC206 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma |
| Cannabidivarin | Phase 2 | Autism Spectrum Disorder |
| JZP3507 | Phase 2 | Meningioma |
| ADX-N05 | Phase 2 | Narcolepsy |
| Paclitaxel | Phase 2 | Gastroesophageal Adenocarcinoma |
| Enasidenib Mesylate | Phase 2 | Recurrent Acute Myeloid Leukemia |
| Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1/2 | Essential Thrombocythemia |
| Sativex and rifampicin | Phase 1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 |
| JZP269 | Phase 1 | |
| CBD-OS | Phase 1 | Focal Seizures |
| JZP047 | Phase 1 | Healthy Participants |
| JZP441 | Phase 1 | Healthy Participants |
| Atezolizumab | Phase 1 | Endometrial Cancer |
| CPX-351 (Cytarabine:Daunorubicin) Liposome Injection | Phase 1 | Hematologic Neoplasms |
Latest
- Cannabidiol moved to Post-Market
- Zanidatamab moved to Phase 3
- Onc206 moved to Phase 2
- Trial Completion Date Pushed 551 Days: Lurbinectedin
- jazz pharmaceuticals filed 8-K
Follow Jazz Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.